Alteogen [196170] is showing a sharp decline intraday on the 25th. Despite Shinhan Investment Securities positively evaluating the strategic value of the Keytruda subcutaneous injection (SC) and the possibility of additional technology out-licensing, the stock price is showing weakness today. As of the morning of the 25th, Alteogen is trading at 299,500 won, down 21,000 won from the previous trading day, a decline of about 6.55%. However, the direction of the report is different. On the 24th, Shinhan Investment Securities maintained a 'Buy' investment opinion and a target price of 480,000 won for Alteogen. Based on the closing price of 320,000 won on the 21st, the upside potential to the target price at that time was estimated at 50%. Researcher Eom Min-yong of Shinhan Investment Securities drew attention to the fact that Moderna's personalized mRNA cancer vaccine 'Intismeran Autogene (V940)' in combination with MSD's Keytruda met the primary endpoints in a Phase 3 clinical trial for melanoma adjuvant therapy. The analysis is that even if the cancer vaccine market expands, Keytruda SC could occupy an important position in combination therapy. Notably, a significant number of the ongoing late-stage V940 solid tumor clinical trials are being conducted in combination with Keytruda, and Keytruda SC was adopted as the combination partner in the Phase 3 trial for high-risk non-small cell lung cancer that began in May. Based on this, Shinhan Investment Securities evaluated Keytruda SC as one of MSD's core strategies. Alteogen's own business momentum was also included in the report. Shinhan Investment Securities cited additional technology out-licensing and clinical progress by existing partners as key variables for judging future corporate value, maintaining Alteogen as its top pick in the pharmaceutical and biotech sector. Despite the securities firm's positive outlook, the stock price is declining today. It cannot be definitively concluded that there is a direct causal relationship between the securities firm's report and the day's stock price movement. Biotech stocks can move sharply depending not only on expectations for clinical trials and technology out-licensing, but also on foreign and institutional supply and demand, profit-taking, the overall market's risk appetite, and the level of expectations already reflected in the stock price. [This article was written with the assistance of AI. This article is not intended to solicit investment or recommend buying or selling specific stocks. The stock market may experience expanded volatility depending on corporate earnings, order progress, domestic and international economic conditions, and changes in supply and demand. Before making investment decisions, it is necessary to sufficiently review corporate disclosures and business progress, and the final responsibility for investment lies with the investor.]